{"symbol":"REGN","fiscalQuarter":"Q1-2013","reportDate":"2013-05-03","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2013","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.05%","keyNumbers":[{"metric":"EPS","actual":"$1.78","expected":"N/A","surprise":"+68.56%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on advancing our pipeline."],"summary":"Management expressed confidence in their financial performance, particularly in EPS. They emphasized their commitment to pipeline development."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, significantly above expectations, contributed to a 7.05% increase in stock price. The positive surprise indicates effective cost management and operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2013 earnings: EPS beat expectations. Stock up 7.05%. Full breakdown."}}